FEEDOTCOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
ENvue Medical, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 17, 2026
$0.50+0.13 (+34.73%)
Close on Oct 19, 2026
- Market cap
- $3.08M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2013 to 2025
Gross margin
6.0%−28.4 pts over 5 years
Operating margin
-896.6%−139.1 pts over 5 years
Net margin
-712.3%−17.9 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -0.2% | +50.3% | +32.6% | +33.0% | |
| Gross profit | -89.9% | -2.9% | -6.5% | +4.6% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 209.1% | -231.3% | -106.6% | |
| Return on assets | -228.6% | -84.3% | -81.3% | |
| Current ratio | 0.39 | 2.75 | 1.09 | |
| Interest coverage | – | -32.1× | – | |
| Inventory turnover | 1.3× | 3.1× | 1.1× | |
| Capex to revenue | 3.5% | 0.3% | 2.4% | |
| Diluted shares | 0M | 0M | 1M |
Where the cash went
Fiscal 2021 to 2025, five years combined
ENvue Medical generated $26.89M from operations and spent $70.00K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$26.89M
Used
$70.00K
Capital expenditure$70.00K100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-712.3%
×Asset turnover0.11×
×Equity multiplier1.31×
=Return on equity, FY2025-106.6%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -712.3% | 0.11× | 1.31× | -106.6% |
| FY2024 | -144.8% | 0.50× | 2.23× | -160.5% |
| FY2023 | -162.5% | 0.36× | 1.74× | -102.8% |
| FY2022 | -724.5% | 0.10× | 1.52× | -114.1% |
| FY2021 | -842.6% | 0.20× | 1.94× | -328.1% |
| FY2020 | -694.4% | 0.12× | 2.74× | -231.3% |
| FY2019 | -1093.2% | 0.29× | 2.00× | -640.2% |
| FY2018 | -1306.3% | 0.10× | 1.57× | -202.8% |
| FY2017 | -2077.4% | 0.09× | 4.72× | -874.9% |
| FY2016 | -1236.2% | 0.18× | -0.91× | 209.1% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$18.19M
- Cash generatingOperating cash flow above zero-$9.37M
- Return on assets improvedROA up on the prior year-55.5% → -501.1%
- Earnings backed by cashOperating cash flow above net income-$9.37M vs -$18.19M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.22 → 1.09
- No dilutionShare count did not rise0M → 1M
- Gross margin improvedGross margin up on the prior year58.95% → 5.99%
- More efficientAsset turnover rose0.38 → 0.70